To access this material please log in or register

Register Authorize

Clinical variants and outcomes of progressive chronic heart failure in individuals with hypertrphic cardiomyopathy

Komissarova S. M.1, Zakharova E. Y.1, Iljina E. V.1, Sevruk T. V.1, Kras'ko O. V.2
1 – State Institution Republican Science and Practice Center "Cardiology", R. Luxemburg 110, Minsk 220036, Republic of Belarus
2 – State Science Institution, "United Institute of Informatics Issues of the Belarus National Academy of Sciences", Surganova 6, Minsk 220012, Belarus

Keywords: hypertrophic cardiomyopathy, chronic heart failure, risk factors

DOI: 10.18087/rhfj.2017.2.2326

Background. Determining the types of clinical course and outcomes of hypertrophic cardiomyopathy (HCMP) with symptoms of progressive CHF is still a complicated and not completely solved issue. The article proposes factors identifying patients with a high risk of CHF progression to a pronounced stage. Aim. To determine the types of clinical course and to evaluate survival, outcomes, and effects of factors associated with CHF progression in patients with HCMP. Materials and methods. Clinical and instrumental data were analyzed for 345 patients with HCMP (199 males and 146 females, median age 47, from 17 to 72) who were managed at the Russian Science and Practice Center “Cardiology” from 2006 through 2016. Results. 12 (3.5%) patients with HCMP (mean age, 46±12; males, 58.3%) had symptoms of NYHA FC III-IV CHF associated with pronounced LV myocardial dysfunction. During the observation period (median duration, 6.7 years), unfavorable outcomes were observed for 8 (67%) of 12 patients with symptoms of FC III–IV CHF: sudden cardiac death in one patient; fatal outcomes caused by CHF progression to a “terminal stage” in 6 patients; and acute cerebrovascular disease with a fatal outcome in one patient. Median event-free survival was 4.3 years. During the observation period, symptoms of CHF progressed from NYHA FC II to FC III in 21 (6.1%) patients. According to results of a multifactorial analysis, predictors of the risk for progression of CHF symptoms from NYHA FC II to FC III included reduced LV EF to <56% (HR, 4.8; 95% CI, from 1.6 to 14.5; p<0.001); increased left atrial (LA) size >47 mm (HR, 9.0; 95% CI, from 3.0 to 27.6; p<0.005); and the pseudonormal type of diastolic dysfunction (HR, 9.6; 95% CI, from 2.8 to 33.4; p<0.001). Percent ratio of myocardial fibrosis to total myocardial volume by data of heart MRI identified patients with a risk of unfavorable remodeling at a threshold level of >25%. Conclusion. Isolation of a HCMP patient subgroup with early signs of disease progression is important for timely modification of the therapeutic tactics. Early administration of a standard therapy with β-blockers, ACE inhibitors or angiotensin II receptor antagonists and mineralocorticoid receptor antagonists will allow controlling progression of the disease.
  1. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. DOI:10.1093/eurheartj/ehu284.
  2. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535–46. DOI:10.1161/CIRCHEARTFAILURE.112.967026.
  3. Fernández A, Vigliano CA, Casabé JH, Diez M, Favaloro LE, Guevara E et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011;108(4):548–55. DOI:10.1016/j.amjcard.2011.03.083.
  4. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216–25. DOI:10.1161/CIRCULATIONAHA.105.583500.
  5. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55. DOI:10.1016/S0140-6736(12)60397-3.
  6. Maron BJ, Ommen SR , Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99. DOI:10.1016/j.jacc.2014.05.003.
  7. Biagini E, Olivotto I, Iascone M, Parodi MI, Girolami F, Frisso G et al. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014;114(5):769–76. DOI:10.1016/j.amjcard.2014.05.065.
  8. Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(5):574–9. DOI:10.1161/CIRCHEARTFAILURE.109.922872.
  9. Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM et al. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail. 2014;7(6):967–75. DOI:10.1161/CIRCHEARTFAILURE.114.001435.
  10. Yacoub MH, Olivotto I, Cecchi F. “End-stage” hypertrophic cardiomyopathy: from mystery to model. Nat Clin Pract Cardiovasc Med. 2007;4(5):232–3. DOI:10.1038/ncpcardio0859.
  11. Lang R , Bierig M, Devereux R , Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI:10.1016/j.euje.2005.12.014.
  12. Lausen B, Hothorn T, Bretz F, Schumacher M. Assessment of Optimal Selected Prognostic Factors. Biometrical Journal. 2004;46(3):364–74. DOI:10.1002/bimj.200310030.
  13. Venables W. N., Ripley В. D. Modern Applied Statistics with S. 4th ed. -New York: Springer-Verlag; 2002. 498 p.
  14. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46(8):1543–50. DOI:10.1016/j.jacc.2005.04.062.
  15. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 1998;81(11):1339–44.
  16. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111–23. DOI:10.1093/eurheartj/ehq136.
  17. Coutu M, Perrault LP, White M, Pelletier GB, Racine N, Poirier NC et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23(4):413–7. DOI:10.1016/S1053-2498(03)00225-0.
  18. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(2):261–7. DOI:10.1016/j.amjcard.2010.03.020.
  19. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(12):1727–31. DOI:10.1016/j.amjcard.2009.07.057.
  20. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.
  21. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006;98(7):960–5. DOI:10.1016/j.amjcard.2006.05.013.
  22. Ciró E, Maron BJ, Bonow RO, Cannon RO, Epstein SE. Relation between marked changes in left ventricular outflow tract gradient and disease progression in hypertrophic cardiomyopathy. Am J Cardiol. 1984;53(8):1103–9.
  23. O’Hanlon R , Grasso A, Roughton M, Moon JC, Clark S, Wage R et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867–74. DOI:10.1016/j.jacc.2010.05.010.
Komissarova S. M., Zakharova E. Y., Iljina E. V., Sevruk T. V., Kras’ko O. V. Clinical variants and outcomes of progressive chronic heart failure in individuals with hypertrphic cardiomyopathy. Russian Heart Failure Journal. 2017;18 (2):107–114

To access this material please log in or register

Register Authorize
Ru En